» Articles » PMID: 15729167

Effect of Pirfenidone on Apoptosis-regulatory Genes in Chronic Cyclosporine Nephrotoxicity

Overview
Journal Transplantation
Specialty General Surgery
Date 2005 Feb 25
PMID 15729167
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Background: : Apoptosis was shown to play a role in the progression of fibrosis in a chronic cyclosporine A (CsA) nephrotoxicity animal model. In addition, the antifibrotic molecule pirfenidone (PFD) was shown to ameliorate fibrosis in this model. We evaluated the role of PFD on the expression of apoptosis-regulatory genes in the kidneys of CsA-treated rats.

Methods: : Rats were administered CsA 7.5 mg/kg per day, CsA+PFD (250 mg/kg/day), vehicle (VH), or VH+PFD, and sacrificed at 28 days. Physiologic and histologic changes were studied, and apoptosis was detected by terminal deoxynucleotide transferase-mediated dUTP nick-end labeling stain. The mRNA expression of pro-apoptotic genes p53 and Fas-ligand was evaluated by quantitative polymerase chain reaction, and that of Bcl-xL, an anti-apoptotic gene, was evaluated by Northern blot analysis. In addition to mRNA expression, immunohistochemical studies of caspase 3 were performed.

Result: : PFD administration to CsA-treated rats significantly ameliorated nephrotoxicity. Apoptosis-positive cells were increased by CsA but significantly reduced by PFD treatment (68+/-19 vs. 3+/-1, P<0.01). In addition, PFD down-regulated the mRNA expression of CsA-induced p53 and Fas-ligand (P<0.01) and increased that of Bcl-xL, previously reduced by CsA (P<0.01). Finally, PFD significantly down-regulated caspase 3 expression, present mostly on renal tubular epithelial cells. None of these changes were observed in VH-treated rats.

Conclusion: : Whereas CsA favored the expression of pro-apoptotic genes, that effect was ameliorated by PFD. Because apoptosis can partly explain the loss of cells associated with fibrosis, the influence of PFD on apoptosis-regulatory genes in a manner that reduces apoptosis may explain some of its antifibrotic properties.

Citing Articles

Fibrosis in Chronic Kidney Disease: Pathophysiology and Therapeutic Targets.

Reiss A, Jacob B, Zubair A, Srivastava A, Johnson M, Leon J J Clin Med. 2024; 13(7).

PMID: 38610646 PMC: 11012936. DOI: 10.3390/jcm13071881.


Algorithmic approach in the management of COVID-19 patients with residual pulmonary symptoms.

Guri A, Groner L, Escalon J, Saleh A Ann Thorac Med. 2023; 18(4):167-172.

PMID: 38058785 PMC: 10697302. DOI: 10.4103/atm.atm_83_23.


Effect of pirfenidone protecting against cigarette smoke extract induced apoptosis.

Ma Y, Liu X, Luo L, Li H, Zeng Z, Chen Y Tob Induc Dis. 2022; 20:24.

PMID: 35291559 PMC: 8886422. DOI: 10.18332/tid/146169.


Commentary: Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused.

Seifirad S, Alquran L Front Med (Lausanne). 2021; 7:625440.

PMID: 33585519 PMC: 7874198. DOI: 10.3389/fmed.2020.625440.


Effect of Prolonged-Release Pirfenidone on Renal Function in Septic Acute Kidney Injury Patients: A Double-Blind Placebo-Controlled Clinical Trial.

Chavez-Iniguez J, Poo J, Ibarra-Estrada M, Garcia-Benavides L, Navarro-Blackaller G, Cervantes-Sanchez C Int J Nephrol. 2021; 2021:8833278.

PMID: 33520317 PMC: 7817311. DOI: 10.1155/2021/8833278.